Haemonetics Stock

Haemonetics EBIT

The EBIT of Haemonetics (HAE) as of Jul 25, 2026 is 241.40 M USD. In the previous year, EBIT was 221.82 M USD — a change of 8.83% (higher).

EBIT

241.40 MUSD

YoY

8.83%

Last updated:

In 2026, Haemonetics's EBIT was 241.40 M USD, a 8.83% increase from the 221.82 M USD EBIT recorded in the previous year.

The Haemonetics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2021
89.75 base
Jan 1, 2022
80.75 base
Jan 1, 2023
156.03 base
Jan 1, 2024
164.88 base
Jan 1, 2025
221.82 base
Jan 1, 2026
241.40 base
Jan 1, 2027 (e)
382.58 base
Jan 1, 2028 (e)
418.76 base
YEAREBIT (M USD)
2028 est 418.76
2027 est 382.58
2026 241.40
2025 221.82
2024 164.88
2023 156.03
2022 80.75
2021 89.75
2020 119.55
2019 83.55
2018 60.68
2017 39.21
2016 -43.94
2015 40.54
2014 47.33
2013 56.44
2012 88.76
2011 110.55
2010 83.28
2009 85.57
2008 70.29
2007 62.75
Access this data via the Eulerpool API

Haemonetics Revenue

Haemonetics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
870.46 M USD
89.75 M USD
79.47 M USD
Jan 1, 2022
993.20 M USD
80.75 M USD
43.38 M USD
Jan 1, 2023
1.17 B USD
156.03 M USD
115.40 M USD
Jan 1, 2024
1.31 B USD
164.88 M USD
117.56 M USD
Jan 1, 2025
1.36 B USD
221.82 M USD
167.68 M USD
Jan 1, 2026
1.33 B USD
241.40 M USD
97.31 M USD
Jan 1, 2027 (e)
1.40 B USD
382.58 M USD
242.44 M USD
Jan 1, 2028 (e)
1.47 B USD
418.76 M USD
261.45 M USD

Haemonetics Margins

Haemonetics stock margins

The Haemonetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Haemonetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Haemonetics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
49.22 %
10.31 %
9.13 %
Jan 1, 2022
53.44 %
8.13 %
4.37 %
Jan 1, 2023
53.30 %
13.35 %
9.87 %
Jan 1, 2024
54.38 %
12.60 %
8.98 %
Jan 1, 2025
57.21 %
16.30 %
12.32 %
Jan 1, 2026
55.74 %
18.10 %
7.29 %
Jan 1, 2027 (e)
55.74 %
27.29 %
17.29 %
Jan 1, 2028 (e)
55.74 %
28.41 %
17.73 %

Haemonetics Stock analysis

What does Haemonetics do? Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Haemonetics's EBIT

Haemonetics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Haemonetics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Haemonetics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Haemonetics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Haemonetics stock

EBIT of Haemonetics is 241.40 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Haemonetics

All Key Metrics — Haemonetics